Affimed N.v Stock News

HEIDELBERG, Germany, Dec. 08, 2021 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today the initiation of patient recruitment for the open-label, multi-center phase 1/2a study evaluating the safety, tolerability, pharmacokinetics and efficacy of the innate cell engager (ICE®) AFM24 in combination with Roches atezolizumab, an anti-PD-L1 checkpoint inhibitor. AFM24 is Affimeds tetravalent, bispecific epidermal growth factor receptor (EGFR)- and CD16A-targeting ICE ® , developed for the treatment of patients with solid tumors.

HEIDELBERG, Germany, Dec. 08, 2021 (GLOBE NEWSWIRE) -- Affimed N.V. (NASDAQ: AFMD ) a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today the initiation of patient recruitment for the open-label, multi-center phase 1/2a study evaluating the safety, tolerability, pharmacokinetics and efficacy of the innate cell engager (ICE®) AFM24 in combination with Roche''s atezolizumab, an anti-PD-L1 checkpoint inhibitor. AFM24 is Affimed''s tetravalent, bispecific epidermal growth factor receptor (EGFR)- and CD16A-targeting ICE ® , developed for the treatment of patients with solid tumors. "Natural killer cells, which are part of the innate immune system, have the ability to recognise cancer cells. AFM24, a novel immunotherapy, aims to redirect and engage these natural killer cells by linking them to a protein called EGFR, which is expressed on many solid tumours, to increase their tumour killing potency," said Dr Juanita Suzanne Lopez, Consultant Medical Oncologist at The Royal Marsden and Clinical Researcher at The Institute of Cancer Research, London and principal investigator for the study. "By combining AFM24 with an immune checkpoint inhibitor, we aim to activate both the innate and the adaptive immune system to improve patient outcomes.

In the last trading session, 3.35 million Affimed N.V. (NASDAQ:AFMD) shares changed hands as the companys beta touched 2.59. With the companys per share price at $6.07 changed hands at -$0.51 or -7.75% during last session, the market valuation stood at $787.83M. AFMDs last price was a discount, traded about -93.41% off its 52-week high Why To Invest In Affimed N.V. (NASDAQ: AFMD) Stock? Read More »

In last trading session, Affimed N.V. (NASDAQ:AFMD) saw 2.08 million shares changing hands with its beta currently measuring 2.57. Companys recent per share price level of $6.75 trading at -$0.07 or -1.03% at ring of the bell on the day assigns it a market valuation of $817.83M. That closing price of AFMDs stock is at Buy, Sell Or Hold Affimed N.V. (NASDAQ:AFMD) At $6.75? Read More »

Affimed, Amgen, and Bristol Myers Squibb are too cheap to ignore right now.

Affimed NV (NASDAQ: AFMD ) has announced interim clinical results from the investigator-initiated Phase 1/2 study evaluating cbNK cells pre-complexed with Affimed''s innate cell engager (ICE) AFM13. Eighteen patients with CD30-positive relapsed or refractory Hodgkin and non-Hodgkin lymphomas were treated with the combination of cbNK cells pre-complexed with AFM13. 16 Full story available on Benzinga.com

NEW YORK , Nov. 22, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ASTR, PRFX, VG, AFMD, and PRVB. Full story available on Benzinga.com

Affimed NV (NASDAQ:AFMD) has announced interim clinical results from the investigator-initiated Phase 1/2 study evaluating cbNK cells pre-complexed with Affimed's innate cell engager (ICE) AFM13. E

The biotech's early-stage trial results are turning heads on Wall Street today.

Positive trial results regarding the company's pipeline are buoying the stock's price.

Affimed N.V. (NASDAQ:AFMD) price closed higher on Friday, November 12, jumping 0.68% above its previous close. >> 7 Top Picks for the Post-Pandemic Economy > 7 Top Picks for the Post-Pandemic Economy

Affimed N.V. (AFMD) CEO Adi Hoess on Q3 2021 Results - Earnings Call Transcript

Affimed N.V. (AFMD) delivered earnings and revenue surprises of -30.77% and -13.34%, respectively, for the quarter ended September 2021.

Affimed (NASDAQ:AFMD) reported its Q3 earnings results on Wednesday, November 10, 2021 at 08:00 AM. Here's what investors need to know about the announcement.

HEIDELBERG, Germany, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, ann